What did @janieray92 actually say?
Not much, honestly, and that's partly a compliment. @janieray92 documented their first Wegovy injection at the 0.25 mg starting dose, walked through the autoinjector steps, and explicitly told viewers: "I'm not telling you to use it. I'm not telling you to buy it." They counted to 10 after the second click and confirmed the yellow indicator dropped fully before removing the pen. The disclaimer was clear and upfront, which is more than most GLP-1 creators manage on day one.
The video is light on medical claims because it's almost entirely procedural. There's no promised weight loss number, no timeline, no dietary stack recommendation. What's here is a person showing you what pressing a button feels like. That framing matters for evaluating what can even be fact-checked.
Does the science back this up?
The injection steps shown are broadly consistent with Novo Nordisk's prescribing guidance, though the 10-second hold time is where things get murky. The 0.25 mg starting dose is the FDA-approved initiation dose for Wegovy (semaglutide 2.4 mg maintenance), designed to reduce early gastrointestinal side effects before dose escalation over 16 to 20 weeks.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) established semaglutide 2.4 mg weekly as producing roughly 14.9% mean body weight reduction over 68 weeks in adults with obesity, which is the evidence base behind this medication. The starting dose phase itself isn't where the clinical action happens, it's the on-ramp. The autoinjector design for Wegovy does use a two-click mechanism with a visual yellow indicator, and confirming full depression before removing the pen is correct per the device instructions for use.
What did they get wrong (or right)?
The 10-second hold is the one technical detail worth flagging. Novo Nordisk's official Wegovy Instructions for Use specify holding the pen against the skin until the yellow bar stops moving, then continuing to hold for an additional 6 seconds before removal. @janieray92 says "I'm gonna count to 10, cause that's what I think," which suggests they're estimating, not following a specific instruction. Counting to 10 probably covers the 6-second requirement in practice, but the reasoning is guesswork rather than instruction-following.
On the other hand, they correctly identified that the yellow indicator needs to be fully down, which is the most important visual confirmation step. They also got the starting dose right: 0.25 mg is the correct initiation dose per the FDA label. And their disclaimer language, while brief, is the kind of framing regulators and platforms should want to see more of. No wild promises, no before-and-after framing on day one.
What should you actually know?
If you're starting Wegovy, a few things this video didn't mention are worth knowing. First, injection site rotation matters. The thigh, abdomen, and upper arm are all approved sites, and rotating them reduces localized tissue reactions (Novo Nordisk prescribing information, 2023). Second, the early nausea associated with GLP-1 receptor agonists is real. In the STEP trials, nausea affected roughly 44% of semaglutide participants versus 16% on placebo (Davies et al., 2021, Lancet). It tends to peak in the first weeks and improve, but it's not trivial.
Third, and this is important for anyone watching a TikTok journey like this one: individual results vary significantly. The 14.9% average weight loss in STEP 1 is a population mean. Some participants lost considerably more, others less. Following someone else's journey is fine for motivation, but it's not a predictor of your outcome. Talk to a licensed prescriber before starting, continuing, or adjusting any GLP-1 therapy.
- The 0.25 mg starting dose is a titration dose, not a therapeutic dose. Don't judge the medication's effectiveness at this stage.
- Wegovy requires a prescription and clinical evaluation. It is not appropriate for everyone with overweight or obesity.
- Compounded semaglutide products are not equivalent to FDA-approved Wegovy and carry different risk profiles.